Clinical Trial Update: Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A [Phase 4]

View source ↗

Summary

Phase 4 trial update from Bayer evaluating the risk of inhibitor formation in previously treated patients with severe Hemophilia A; the study status is terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Factor VIII replacement therapy (Bayer product) (recombinant factor VIII)

Snippet

Sponsor: Bayer | Conditions: Hemophilia A | Phase 4 | Status: TERMINATED